Catalyst Wire Dossier Catalyst Wire Dossier

Tudriqev

vusolimogene oderparepvec-wtpg
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Tudriqev. Get the full timeline:

Most recent: FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma

See pricing